AGN 190299: a metabolite of the synthetic retinoid AGN 190168; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
tazarotenic acid : A thiochromane that is acetylene in which the hydrogens are replaced by 5-carboxypyridin-2-yl and 4,4-dimethylthiochroman-6-yl groups. It is the active form of the prodrug tazarotene. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 147525 |
| CHEMBL ID | 1201375 |
| CHEBI ID | 73129 |
| SCHEMBL ID | 678713 |
| MeSH ID | M0239814 |
| Synonym |
|---|
| 6-(4,4-dimethyl-thiochroman-6-ylethynyl)-nicotinic acid |
| tazarotenic acid |
| 118292-41-4 |
| 6-(2-(4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid |
| agn 190299 |
| agn-190299 |
| chebi:73129 , |
| CHEMBL1201375 |
| 6-[2-(4,4-dimethyl-2,3-dihydrothiochromen-6-yl)ethynyl]pyridine-3-carboxylic acid |
| A803905 |
| 6-[2-(4,4-dimethyl-2,3-dihydro-1-benzothiopyran-6-yl)ethynyl]-3-pyridinecarboxylic acid |
| 6-((3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)-3-pyridinecarboxylic acid |
| unii-85fdj14553 |
| 3-pyridinecarboxylic acid, 6-((3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)- |
| 85fdj14553 , |
| 6-[2-(3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl]-3-pyridine carboxylic acid |
| FT-0674823 |
| 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid |
| 6-[(4,4-dimethyl-3,4-dihydro-2h-1-benzothiopyran-6-yl)ethynyl]nicotinic acid |
| 3-pyridinecarboxylicacid, 6-[2-(3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl]- |
| SCHEMBL678713 |
| AKOS024123908 |
| IQIBKLWBVJPOQO-UHFFFAOYSA-N |
| 6-[2-(4,4-dimethylthiochroman-6-yl)ethynyl] nicotinic acid |
| 6-(4,4-dimethylthiochroman-6-ylethynyl) nicotinic acid |
| 3-pyridinecarboxylic acid, 6-(2-(3,4-dihydro-4,4-dimethyl-2h-1-benzothiopyran-6-yl)ethynyl)- |
| 6-[(4,4-dimethyl-3,4-dihydro-2h-thiochromen-6-yl)ethynyl]pyridine-3-carboxylic acid |
| agn 190299;agn-190299;agn190299 |
| DTXSID60152094 |
| J-003730 |
| C21518 |
| tazarotenic acid, >=98% (hplc) |
| tazarotenic acid (agn 190299) |
| BCP07476 |
| tazarotenic |
| Q27140328 |
| bdbm393290 |
| us9963439, tazarotenic acid |
| ddbep |
| A14347 |
| HMS3740M05 |
| HY-101108 |
| 6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinicacid |
| AS-76893 |
| CS-0020860 |
| E85141 |
| Role | Description |
|---|---|
| keratolytic drug | A drug that softens, separates, and causes desquamation of the cornified epithelium or horny layer of skin. Keratolytic drugs are used to expose mycelia of infecting fungi or to treat corns, warts, and certain other skin diseases. |
| teratogenic agent | A role played by a chemical compound in biological systems with adverse consequences in embryo developments, leading to birth defects, embryo death or altered development, growth retardation and functional defect. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| monocarboxylic acid | An oxoacid containing a single carboxy group. |
| thiochromane | Any organic heterobicyclic compound consisting of a benzene ring fused to a thiopyran. |
| retinoid | Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof. |
| pyridines | Any organonitrogen heterocyclic compound based on a pyridine skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1665619 | AUC (0.5 to 6 hrs) in C57BL/6 mouse serum at 9.14 umol/kg, ip by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17 | A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators. |
| AID1665656 | Hepatotoxicity in C57BL/6 mouse assessed effect on Rarres2 gene expression in kidney at 9.14 umol/kg, ip administered once daily for 7 days by Trizol reagent based RT-qPCR analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17 | A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators. |
| AID1665630 | Brain to serum concentration ratio, Kp of the compound in C57BL/6 mouse at 9.14 umol/kg, ip by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17 | A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators. |
| AID1846360 | Induction of glucose-stimulated insulin secretion in rat INS-1 832/13 cells incubated for 5 mins by ELISA assay | 2021 | Bioorganic & medicinal chemistry letters, 06-01, Volume: 41 | FFAR1/GPR40: One target, different binding sites, many agonists, no drugs, but a continuous and unprofitable tug-of-war between ligand lipophilicity, activity, and toxicity. |
| AID1665608 | AUC (0.5 to 6 hrs) in C57BL/6 mouse brain at 9.14 umol/kg, ip by LC-MS/MS analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17 | A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators. |
| AID1665655 | In vivo agonist activity at RAR in C57BL/6 mouse assessed upregulation of Adam10 gene expression in brain at 9.14 umol/kg, ip administered once daily for 7 days by Trizol reagent based RT-qPCR analysis | 2020 | Journal of medicinal chemistry, 09-10, Volume: 63, Issue:17 | A CNS-Targeting Prodrug Strategy for Nuclear Receptor Modulators. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.50) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||